Ionis Pharmaceuticals Inc (IONS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$56.02-1.22%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — TRYNGOLZA peak net sales exceed $2 billion: Pelacarsen Phase 3 missed primary endpoint (0% success) vs >$2B TRYNGOLZA target.
Ionis is growing revenue about 20% a year. DAWNZERA sales aim for $110-120 million in 2026. TRYNGOLZA has FDA approval and targets over $2 billion in peak sales. Recent earnings beats and partnerships support growth.
Ionis is still loss-making with negative EPS expected in 2026. Revenue growth depends on a few key drugs that may not meet sales targets. Management is volatile and the stock trades below Street median price targets.
The market prices in about 27% revenue growth and values Ionis slightly below our fair value of $93. Our fair value is 18% below the Street median, reflecting cautious optimism. We see room for growth but risks remain.
Breaks if: DAWNZERA sales fall below $100 million in FY26
Breaks if: EPS loss worsens beyond -$1.0 per share in FY27
Breaks if: YoY revenue growth falls below 15% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. IONS is focused on achieving significant revenue growth and expanding product sales, but it operates in a challenging environment with moderate risk factors.
The market currently reflects a low level of fragility and has priced in expectations that are somewhat below peers. The valuation suggests that IONS is seen as relatively cheap compared to its competitors, but there is an expectations gap indicating that the market is cautious.
Management is on track to meet its revenue growth goals and is making progress with product sales. However, the company operates in a high-miss-rate industry, which introduces some uncertainty despite a low probability of missing its targets.
The long-term thesis hinges on management's ability to maintain guidance and deliver on revenue targets. Key factors include the performance of sector bellwethers and broader economic conditions that could impact the healthcare sector.
The most important moves since the prior daily snapshot.
Company momentum fell by 17.8 points (from 80.0 to 62.2).
Mixed, the news cuts both ways. The company beat earnings expectations recently. It reported Q2 revenue of $268 million, exceeding estimates. However, its drug pelacarsen failed in a late-stage trial. This failure lowers expectations for future revenue from that drug. Institutional interest also decreased, with hedge funds dropping to 54.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: TRYNGOLZA peak sales potential drops below $1.5 billion
Overall, IONS presents a mixed picture with growth potential balanced against industry risks. Not investment advice.